Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
BioBlast®
Biosimilars Deals 2023
Biosimilars Deals 2024
Diversity
Masterclasses
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Patents
PipCast®
PTE
Trade Marks
Webinars
Pearce IP BioBlast® w/e 17 December 2021

Pearce IP BioBlast® w/e 17 December 2021

11 Dec 21 | Samsung Bioepis announced that SB12 (proposed eculizumab biosimilar) met all the endpoints in a Ph I study. 13 Dec 21 | Xbrane Biopharma announced it is developing two new biosimilar candidates referencing Keytruda® (pembrolizumab) and Darzalex®...
Pearce IP BioBlast® w/e 17 December 2021

Pearce IP BioBlast® w/e 10 December 2021

06 Dec 21 | AU | Australia’s TGA provisionally approved Celltrion’s Regkirona® (regdanvimab) for the treatment of adults with coronavirus who do not require supplemental oxygen and are at increased risk of progressing to severe COVID-19. 07 Dec 21 | Alvotech and...
Pearce IP BioBlast® w/e 17 December 2021

Pearce IP BioBlast® w/e 03 December 2021

01 Dec 21 | CN | Tot Biopharm announced that China’s NMPA has approved Pusintin® (biosimilar bevacizumab) for the treatment of patients with advanced, metastatic or recurrent non-squamous non-small cell lung cancer and patients with metastatic colorectal cancer. 01...
Pearce IP BioBlast® w/e 17 December 2021

Pearce IP BioBlast® w/e 26 November 2021

21 Nov 21 | CN | Innovent released the results of a Ph III study of sintilimab and BYVASDA® (bevacizumab biosimilar) combined with chemotherapy in patients with EGFR-mutated non-squamous non-small cell lung cancer who progressed after EGFT-TKI therapy. 22 Nov 21 |...
Pearce IP BioBlast®: w/e 19 November 2021

Pearce IP BioBlast®: w/e 19 November 2021

15 Nov 21 | EU | Celltrion announced that the EC has approved Regkirona® (regdanvimab, CT-P59) for adults with COVID-19 who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID-19. 16 Nov 21  | US | Viatris and Biocon...